Patents by Inventor Michael Xia

Michael Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250019366
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N—{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Application
    Filed: June 10, 2024
    Publication date: January 16, 2025
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • Publication number: 20250020629
    Abstract: Semiconductor devices can include features to apply electrical stimulation to liquids in which material is present and to measure the response to the electrical stimulation.
    Type: Application
    Filed: July 10, 2024
    Publication date: January 16, 2025
    Inventors: Phillip Michel Nadeau, David Duncan Lloyd, Michael C.W. Coln, Roman Trogan, Junfei Xia, Marek Hempel, Chen Yang, Ramji Sitaraman Lakshmanan
  • Publication number: 20240376106
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 24, 2024
    Publication date: November 14, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • Publication number: 20240368171
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Application
    Filed: July 16, 2024
    Publication date: November 7, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Patent number: 12071439
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: August 27, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Publication number: 20240246982
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 25, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Patent number: 12043614
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: July 23, 2024
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • Patent number: 12024522
    Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: July 2, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Lei Qiao, Lingkai Weng, Chongsheng Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou, Jianji Wang
  • Publication number: 20240166655
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 23, 2024
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia, Weiguo Liu
  • Patent number: 11905292
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 20, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia, Weiguo Liu
  • Patent number: 11897889
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 13, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Publication number: 20230406852
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: December 21, 2023
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • Patent number: 11780836
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • Publication number: 20230192722
    Abstract: The present invention relates to salts and solid forms of the FGFR inhibitor (7R,8aS)-2-(5-(5-(2,3-Dimethylphenyl)-6-methoxy-1H-pyrazolo[4,3-b]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-a]pyrazin-7-ol, including methods of preparation thereof, wherein the compounds, salts, and solid forms are useful in the treatment of FGFR-mediated diseases such as cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 22, 2023
    Inventors: Pingli Liu, Zhongjiang Jia, Qiyan Lin, Naijing Su, Timothy Martin, Michael Xia, Jiacheng Zhou, Baoyu Mi
  • Publication number: 20230111912
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Application
    Filed: November 7, 2022
    Publication date: April 13, 2023
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • Publication number: 20230059389
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 23, 2023
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Patent number: 11505540
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: November 22, 2022
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Qun Li
  • Patent number: 11472801
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • Publication number: 20220144830
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • Publication number: 20220056034
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia